Septerna, Inc.

NASDAQ:SEPN

Biotechnology

Healthcare
$39.45 -2.04%

-$0.73 today

Market cap
$1.88B
Beta
2.38
P/E (TTM)
-43.6
EPS (TTM)
-$0.81
52W Low $9.96High $37.32

Volume 0.30M

Average 0.32M

SEPN Account Payables

Amounts the company owes suppliers for goods and services received.

Septerna, Inc.NASDAQ: SEPN

Account Payables · Q3 FY2026 · quarter ended Sep 2026

Account payables rises 86.7% from a year ago

Account payables stood at $6.96M at the end of Q3 FY2026, up 86.7% from a year earlier and up 75.4% from the prior quarter. Over 3 fiscal years it compounded at +49.6% a year.

Context

  • Account payables amounted to 1.1% of total assets at the end of Q3 FY2026, up 0.5 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +86.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$6.96M+75.4% QoQ
Last fiscal yearDec 2025
$10.28M+221.3% YoY
Year agoSep 2025
$3.73M+86.7% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+86.7%——
1 year+221.3%——
3-year CAGR+49.6%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
10.28M USD
Year-over-year change
+221.3%
3-year CAGR
+49.6%

Account Payables vs competitors

How SEPN compares with its peers on the latest reported figures

  • SEPN's Sep 2026 account payables of $6.96M is the 3rd highest of the 7 companies compared; the peer median is $6.81M.
  • Its year-over-year change of +86.7% is the highest of 6, against a peer median of +62.8%.
  • Account payables amounts to 1.1% of total assets for SEPN, versus a peer median of 1.5%.
SEPN Competitors Peer median
Account Payables for SEPN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
KLRAKailera Therapeutics, Inc.Jun 2026$19.2M ——1.6%
GPCRStructure Therapeutics Inc.Jun 2026$11.13M +23.8%+32.1%0.8%
SEPNSepterna, Inc.Sep 2026$6.96M +86.7%+49.6%1.1%
VTVTvTv Therapeutics Inc.Mar 2026$6.82M +62.8%-22.8%6.9%
MBXMBX Biosciences, Inc. Common StockSep 2026$6.81M +80.6%+45.0%1.4%
BMEABiomea Fusion, Inc.Mar 2026$4.61M -40.1%-22.1%9.9%
MAZEMaze Therapeutics, Inc.Mar 2026$4.01M +66.9%+4.2%1.0%
Peer median (excluding SEPN) $6.81M+62.8%+4.2%1.5%

Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents30.61M88.48M238.2M120.72M
Short-term Investments00112.73M270.37M
Net Receivables022.78M1.12M13.74M
Inventory0000
Other Current Assets204K92K200K1.15M
Total Current Assets31.89M112.68M356.82M410.96M
Property, Plant & Equipment (Net)3.11M17.19M28.69M25.93M
Goodwill0000
Intangible Assets0000
Long-term Investments0069.87M0
Tax Assets0000
Other Non-current Assets1.12M1M1.17M159.29M
Total Non-current Assets4.23M18.19M99.73M185.22M
Total Assets36.12M130.87M456.55M596.19M
Account Payables3.07M2.64M3.2M10.28M
Short-term Debt0000
Tax Payables0200K00
Deferred Revenue00062.27M
Other Current Liabilities1.76M3.04M4.21M6.07M
Total Current Liabilities5.54M6.91M12.85M86.93M
Long-term Debt00021.41M
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities74.78M149.76M33K105.92M
Total Non-current Liabilities74.78M162.33M23.66M127.33M
Total Liabilities80.32M169.24M36.51M214.26M
Common Stock3K3K44K45K
Retained Earnings(50.76M)(46.58M)(118.37M)(167.25M)
Accumulated OCI0056K617K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(44.2M)(38.37M)420.05M381.93M
Total Debt710K12.57M25.48M23.63M
Net Debt(29.9M)(75.92M)(212.72M)(97.1M)

Septerna, Inc.

NASDAQ:SEPN

Intrinsic Alpha fair value

Locked

Current Price

$39.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.